Publikationen in Zusammenarbeit mit Forschern von Hospital Morales Meseguer (28)

2024

  1. The effectiveness of adjustable trans-obturator male system (ATOMS) in radiated patients is reduced: A propensity score-matched analysis

    BJUI Compass, Vol. 5, Núm. 4, pp. 506-514

2023

  1. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

    European urology oncology, Vol. 6, Núm. 1, pp. 58-66

  2. Impact of the COVID-19 Pandemic on Cancer Diagnosis in Madrid (Spain) Based on the RTMAD Tumor Registry (2019–2021)

    Cancers, Vol. 15, Núm. 6

  3. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

  4. Results of Adjustable Trans-Obturator Male System in Patients with Prostate Cancer Treated with Prostatectomy and Radiotherapy: A Multicenter Study

    Journal of Clinical Medicine, Vol. 12, Núm. 14

2022

  1. ATOMS (Adjustable transobturator male system) is an effective and safe second‐line treatment option for recurrent urinary incontinence after implantation of an advance/advance XP fixed male sling. a multicenter cohort analysis

    Journal of Clinical Medicine, Vol. 11, Núm. 1

  2. Competency assessment of residents of Intensive Care Medicine through a simulation-based objective structured clinical evaluation (OSCE). A multicenter observational study

    Medicina Intensiva, Vol. 46, Núm. 9, pp. 491-500

2021

  1. Seghi study: Defining the best surveillance strategy in hodgkin lymphoma after first-line treatment

    Cancers, Vol. 13, Núm. 10

2020

  1. Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study

    European Journal of Internal Medicine, Vol. 78, pp. 63-68

  2. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

2019

  1. Continuous Positive Airway Pressure Treatment Does not Reduce Uric Acid Levels in OSA Women

    Archivos de Bronconeumologia, Vol. 55, Núm. 4, pp. 201-207

  2. Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)

    Revista Espanola de Cardiologia, Vol. 72, Núm. 12, pp. 1020-1030

2018

  1. Immunocompromised patients with acute respiratory distress syndrome: Secondary analysis of the LUNG SAFE database

    Critical Care, Vol. 22, Núm. 1

  2. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  2. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

    Tumor Biology, Vol. 39, Núm. 6

  3. Effect of continuous positive airway pressure on blood pressure and metabolic profile in women with sleep apnoea

    European Respiratory Journal, Vol. 50, Núm. 2

  4. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Continuous positive airway pressure improves quality of life in women with obstructive sleep apnea a randomized controlled trial

    American Journal of Respiratory and Critical Care Medicine, Vol. 194, Núm. 10, pp. 1286-1294

  2. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Critical Care, Vol. 20, Núm. 1